RMI2

Across TCGA pan-cancer cohorts, RMI2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RMI2 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RMI2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RMI2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC and LSCC are the cancer types where RMI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.893	0.468	.005	50	view →
LSCC	OS	Quartile	All	1.000	0.797	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RMI2–HNSC (OS)

Open the HNSC breakdown →